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Summary 9gmTc-sestamibi (SSmTc-MIBI) is a substrate for the P-glycoprotein (P-gp) pump but it is not known whether it is a substrate for the
multidrug resistance-associated protein (MRP) pump. Therefore, 99mTc-MIBI was evaluated in the GLC4 cell line and its doxorubicin-resistant
MRP-, but not P-gp-, overexpressing GLC4/ADR sublines as well as in the Si cell line and its MRP-transfected subline Sl-MRR 99mTc-MIBI
concentration decreased in the GLC4/ADR sublines with increasing MRP overexpression and was lower in S1-MRP than in Si. 99mTc-MIBI
plus vincristine increased 99mTc-MIBI concentration in GLC4 lines compared with 99,"Tc-MIBI alone. 99,"Tc-MIBI efflux raised with increasing
MRP expression in the GLC4 lines. Glutathione depletion elevated 99mTc-MIBI concentration in GLC4/ADR15,x. Cross resistance for 99Tc-MIBI,
used to test cytotoxicity of the Tc compound, was observed in GLC4/ADR,50X vs GLC4. 99Tc-MIBI induced a synergistic effect on vincristine
cytotoxicity in GLC4/ADR15oX. These results show that 99mTc-MIBI is involved in MRP-mediated efflux. The fact that 99mTc-MIBI efflux is
influenced by MDR1 and MRP expression must be taken into account when this y-rays-emitting complex is tested for tumour efflux
measurements.
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Resistance of tumours to chemotherapeutic compounds is an
important problem in the clinic. Drugs such as anthracyclines,
vinca alkaloids and epipodophyllotoxins are involved in the so-
called multidrug resistance (MDR) (Pastan and Gottesman, 1987;
Bradley et al, 1988; De Vries et al, 1989; De Jong et al, 1990;
Meijer et al, 1990; Cole et al, 1992; Versantvoort et al, 1992;
Scheper et al, 1993).
One ofthe mechanisms involved in MDRis the overexpression,
in tumour cells, of the ATP-dependent 170-kDa P-glycoprotein
(P-gp) encoded by the MDR] gene (Endicott and Ling, 1989).
P-gp acts as a transmembrane efflux pump that transports
chemotherapeutic compounds out of the cell, resulting in drug
resistance. P-gp is also expressed in many normal human tissues,
such as the liver (bile canaliculi), pancreas, colon, jejunum and
kidney (Thiebaut et al, 1987; Sugawara et al, 1988). In normal
tissues, P-gp is considered to act as a transporter oftoxins.
Drugs that are substrates for P-gp are hydrophobic and mostly
positively charged atneutral pH. Piwnica-Worms et al (1993) have
shown that 99mTc-sestamibi (99mTc-MIBI), a lipophilic cationic
radiopharmaceutical, is also a substrate for P-gp-mediated trans-
port (Piwnica-Worms et al, 1993; Vallabhaneni et al, 1994;
Ballinger et al, 1995). Consequently, 99-Tc-MIBI allowed visual-
ization of P-gp-mediated efflux in tumours in the animal model
(Piwnica-Worms et al, 1993).
Apart from P-gp, another pump, the multidrug resistance-associ-
atedprotein (MRP), is involved in MDR. The MRP pump was iden-
tified and characterized as a member of the ATP-binding cassette
superfamily (Cole et al, 1992; Ishikawa, 1992; Jedlitschky et al,
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1994). In MRP-transfected cell lines, it was shown that this pump
canbe involved indrug efflux (Zaman etal, 1994). However, differ-
ences in doxorubicin accumulation between doxorubicin-sensitive
and -resistant MRP-overexpressing cell lines were not observed in
all cell lines (Scheper et al, 1993). It was shown with inside-out
vesicles that MRP functions as a glutathione S-conjugate carrier.
Multivalentanionicconjugates, suchasglutathioneS-conjugates are
substrates for this pump (Muller et al, 1994). In contrast to P-gp,
MRP is present in almost all cells ofthe human body.
Detection of protein and RNA expression for the MDR1 and
MRPpump canbeperformed inhuman tumour samples. However,
detection of P-gp or MRP does not necessarily provide any infor-
mation about the function ofthese pumps in the respective tissues.
Studies with modulators of MDR1, such as quinidine and
cyclosporin A, as additional treatment in chemotherapy regimens,
have been disappointing in patients with solid tumours (Wishart et
al, 1994). Therefore, studies have been initiated in the clinic with
the radiopharmaceutical 99-Tc-MIBI to image the effectofmodula-
tors on MDR1-mediated efflux. This may help to select patients
who might benefit most from treatment with modulators. A
compl.icating factoris the fact that, in drug-resistantcells, P-gp and
MRP can be overexpressed at the same time (Brock et al, 1995).
Currently, it is not known whether 9"-Tc-MIBI is also a specific
substrate for MDR1. Therefore, in the present study, 99-Tc-MIBI
kinetics in cell lines with P-gp and.different MRP expression as
well as the effect of99Tc-MIBI on cytotoxicity were analysed.
MATERIALS AND METHODS
Chemicals
Doxorubicin was obtained from Pharmacia Carlo Erba (Milan,
Italy), vincristine from Eli Lilly (Indianapolis, IN, USA) and
verapamil from Knoll (Almere, The Netherlands). RPMI 1640
353354 NH Hendrikse etal
medium, fetal calf serum (FCS) and geneticin were purchased
from Gibco (Paisley, UK), D,L-buthionine S,R-sulphoximine
(BSO) and 3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyl-tetrazolium
bromide (MTT) from Sigma (St Louis, MD, USA), Dulbecco's
modified Eagle medium (DMEM) and HAM F12 medium from
Flow Laboratories (Irvine, UK).
Solid NH4 99TcO4 was kindly provided by Dr Hector Knight
(Mallinkrodt Medical, Petten, The Netherlands) and Cardiolite
vials by Dr Stephen Haber (Du Pont Merck, Billerica, MA, USA).
99mTc-MIBI was synthesized with a one-step Cardiolite kit
formulation containing 0.075 mg of solid stannous chloride as
a reducing agent for technetium (Tc) and excess hexakis(2-
methoxyisobutyl isonitrile) (MIBI) as the Cu(MIBI)4BF4 salt. A
total of 10-12 GBq [99mTc]TcO4- obtained from a commercial
molybdenum/Tc generator (Ultra-TechneKowFM) was added to
the kit reaction vial, heated at 100°C for 10 min and allowed to
cool to room temperature. Radiochemical purity was > 98% by
thin-layer chromatography (Gelman Sciences, Ann Arbor, MI,
USA) with 0.9% sodium chloride as mobile phase. In addition,
macroscopic quantities of 99Tc-MIBI for cytotoxicity experiments
were prepared by the reaction ofNH499TcO4 with Cardiolite vials.
Solid NH499TcO4 (100 mg, 0.55 mmol) was dissolved in 2 ml of
0.9% sodium chloride, filtered and thereafter diluted with 0.9%
sodium chloride until a final volume of 5 ml. As 99Tc-MIBI is a
W-emitter (t12 = 2.1 x 105 a, P- 0.3 MeV), this stock solution was
calibrated using a ,- counter (Packard Instruments, Downers
Grove, IL, USA). A Cardiolite kit was dissolved in 0.65 ml of
stannous chloride solution (8.4gmol ml Sn2+). Thereafter,
37 MBq Na99mTcO4 eluate and 15 gl of the NH499TcO4 stock solu-
tion (1.1 Igmol, 0.2 mg) was added. The kit reaction vial was
heated at 100°C for 15 min and allowed to cool to room tempera-
ture, producing an almost quantitative yield of the 99Tc(MIBI)6+
complex. The reaction mixture was loaded onto a C-18 Sep Pak
cartridge (Waters Associates, Milford, MA, USA). The Sep Pak
cartridge was pre-wet with 5 ml of ethanol, followed by a 10-ml
water rinse. The cartridge was washed with 10 ml of0.9% sodium
chloride and the pure complex was eluted with ethanoll0.9%
sodium chloride (95:5.5 ml). The radiochemical purity was > 97%
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Figure 1 Cellular 99mTc-MlBl accumulation (j.axis) after 1-h exposure
to 99mTc-MIBI in GLC4,GLC4/ADR2., GLC4/ADR,O and GLC4/ADR,,0 cells
(x-axis). Data express the mean ± s.d. of three independent experiments,
each performed in duplicate. Compared with GLC4, the cellular "mTc-MIBI
accumulation was lower in GLC4/ADR2, (P <0.0125), GLC4/ADR,O. (P <0.01)
andGLC4/ADR,50, (P < 0.005)
by thin-layer chromatography. The chemical structure was
confirmed by ion-spray mass spectrometry (Nermag, Argenteuil,
France). This yielded a single peak at m/z = 777 with characteristic
major fragments at 664 (99Tc-MIBI5)+ and 551 (99Tc-MIBI4)+. The
solution was evaporated (37°C, under a nitrogen atmosphere).
99Tc-MIBI6Cl was dissolved in ethanoll0.9% sodium chloride 1:9
(v/v). The solution was calibrated using the abovementioned 1-
counter. The final concentrations of the different solutions were
between 3 and 7 mM 99Tc-MIBI. In addition, to avoid ethanol-
induced effects in 99Tc-MIBI cytotoxicity experiments, the stock
solution of 99Tc-MIBI in ethanol was diluted to 300 gM 99Tc-MIBI
as the highest concentration (< 1% ethanol in the MTA controls).
Cell lines
The human ovarian cancer cell line, A2780 and its 92-fold doxoru-
bicin-resistant MDRI-overexpressing but MRP-negative subline
A2780AD were cultured in RPMI 1640 medium/10% FCS in a
humidified atmosphere with 5% carbon dioxide at 37°C (Zijlstra et
al, 1987). Stable resistance in the A2780AD cell line was assured
by culturing this line with 2 gM doxorubicin twice a week. Before
use, A2780AD was cultured without doxorubicin for 14 days.
The human small-cell lung cancer cell line GLC4 and its
doxorubicin-resistant MRP overexpressing, P-gp-negative sublines
GLC4/ADR2x, GLC4/ADR1Ox andGLC4/ADR150X with two-fold, 10-
fold and 150-fold resistance, respectively, to doxorubicin were
cultured in RPMI 1640 medium/10% FCS in a humidified atmos-
phere with 5% carbon dioxide at 37°C (Zijlstra et al, 1987; De Jong
et al, 1990; Meijer et al, 1991; Versantvoort et al, 1995a). GLC4
expresses alow level ofMRP. MRP mRNA wasoverexpressed in all
GLC4-resistant sublines with a higher expression with increasing
doxorubicin resistance (Muller et al, 1994). Resistance to doxoru-
bicin in these resistant cell lines was assured by culturing
GLC4/ADR2. and GLC4/ADR,IX, respectively, with 0.018gM and
0.59gM doxorubicin once every 3 weeks and GLC4/ADR15M with
1.2gM doxorubicin twice a week. Before use, the resistant cell lines
were cultured without doxorubicin for 21 days. In addition, on a
regularbasis, mdrl-RNAexpression andP-gpexpression were char-
acterized in GLC4 and GLC4 sublines. Both were always negative.
The human non-small-cell lung cancer cell line SW-1573/S1 and
its stable MRP-overexpressing subline S1-MRP were kindly
provided by Professor Dr P Borst and Dr G Zaman, Dutch Cancer
Institute, Amsterdam, The Netherlands. They were cultured in
DMEM medium/10% FCS in a humidified atmosphere with 5%
carbon dioxide at 37°C. The MRP-overexpressing cell line was
obtained after transfection of SW-1573/S1 cells with an expression
vector containing MRP cDNA and a neo gene (pRc/RSV-MRP),
followedby selectionwithgeneticin(Zaman etal, 1994). In addition,
the MRPexpression was negative in SI and positive in S1-MRP.
Cellular 99mTc-MIBI accumulation and efflux
Cells (2 x 106) from A2780, GLC4, S1 and their resistant sublines
were incubated in polystyrene tubes for 1 h at 370C with
64 fm 99mTc-MIBI in 5 ml of RPMI 1640/10% FCS. The different
cells lines were initially incubated with99mTc-MIBI for 15 min and
1 h. Because the steady state of99mTc-MIBI was reached within 1 h
of incubation, further experiments were performed with 1-h drug
incubation. To study modulating effects, A2780 and its resistant
subline were incubated simultaneously with 99mTc-MIBI (64 fM)
and verapamil (50JM), and GLC4 and its resistant sublines were
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Figure 2 Cellular 99mTc-MIBI accumulation (y-axis) in GLC4, GLC4/ADR2,,
GLC4/ADR,OX, GLC4/ADR,1, cells (x-axis) after 1-h 99mTc-MIBI incubation plus
(M) or minus (a) 20 gm vincristine and of GLC4 and GLC4/ADR,, with () or
without (U) pretreatment with 25gM BSO followed by 1-h 9mTc-MIBI
exposure. Data are expressed as mean ± s.d. of three independent
experiments, each performed in duplicate. Compared with 99mTc-MIBI alone,
the cellular "mTc-MIBI concentration plus vincristine as well as the cellular
99mTc-MIBI concentration after pretreatment with BSO was higher in GLC4
(P< 0.0005), GLC4/ADR2, (P < 0.0005), GLC4/ADR1O1 (P < 0.0005) and
GLC4/ADR15,X (P< 0.0005)
incubated with 99mTc-MIBI (64 fM) and vincristine (20gM) for 1 h.
After the incubation, the cells were washed with 5 ml of ice-cold
phosphate-buffered saline (PBS) followed by centrifugation (5
min, 180g, 40C). The wash step as described above was repeated
three times. The cellular 99mTc-MIBI was measured in water with a
y-counter (LKB Wallac, Turku, Finland). Correction of the extra-
cellular adhesion of 99mTc-MIBI to the cells was performed by
subtracting the results obtained after 99mTc-MIBI incubation for 5
min at 40C. Extracellular adhesion of99mTc-MIBI was always less
than 5% compared with the cellular accumulation of 99mTc-MIBI.
The cellular accumulation was expressed as attomol 99-Tc-MIBI
per 106 cells. For efflux studies, 2 x 106 cells from these cell lines
were incubated in 5 ml of RPMI 1640/10% FCS for 1 h at 370C
with 64 fM 99,Tc-MIBI as described above. Thereafter, the cells
were washed with RPMI 1640/10% FCS at 370C. After0, 10 or 30
min, the efflux of 99mTc-MIBI was terminated by adding ice-cold
PBS followed by centrifugation (5 min, 180g, 4°C) and measure-
ment ofthe cellular 99mTc-MIBI. After correction for extracellular
adhesion of99-Tc-MIBI, efflux was expressed as % 99mTc-MIBI in
the cells related to the amount of 99mTc-MIBI after 1 h of 99mTc-
MIBI incubation. Three to six independent experiments were
performed, each in duplicate.
To check the effect ofdifference in cellular 99mTc-MIBI accumu-
lation on cellular efflux of99mTc-MIBI, 2 x 106 cells from GLC4 and
GLC4/ADR10, were incubated with 8 MBq (64 fM). Because
accumulation of 99-Tc-MIBI was found to be four fold higher in
GLC4, than inGLC4/ADR150x, GLC4 andGLC4/ADR150x were incu-
bated at4°C for 1 h with 8 MBq (64 fM) and 2 MBq (16 fM) respec-
tively. After incubation with 99mTc-MIBI at equal levels, the efflux
study was started as described above at a temperature of370C.
The effect of glutathione depletion on 99mTc-MmBI accumulation
was analysed inGLC4 andGLC4/ADR_,^O. Cells wereprecultured for
24 h in the presence of 25 JM of the glutathione synthesis inhibitor
BSO. After 24h, glutathione is no longer detectable in these lines,
without growth delay or loss of viability (Meijer et al, 1991). After
24h, the cell lines were incubated for 1 h with 9"mTc-MIBI as
described above. Three independent experiments were performed,
each in duplicate.
Cytotoxicity assay
The microculture tetrazolium assay (MTA) was used as described
before (Steel and Peckham, 1979). Cells, 3750 and 10 000 perwell
for GLC4 and GLC4/ADR150X, respectively, were incubated for 1 h
with 99Tc-MIBI in a concentration range from 0.5 JM to 300gM in
0.1 ml ofculture medium. Thereafter, the cells were washed three
times by removal of medium after centrifugation (10 min, 180g)
followed by addition of fresh medium and were cultured for 4
days. The percentage cell survival was calculated as the mean of
test samples/mean of untreated samples. Controls consisted of
media without cells (background extinction) and cells incubated
with medium instead of the drug. Two independent experiments
were performed, each in quadruplicate. From these survival
curves, the 99Tc-MIBI concentrations were determined that inhib-
ited cell survival by 10% (ICIO) or 25% (IC25).
IC1o and IC25 concentrations of 99Tc-MIBI were used to test the
modulating effect of 99Tc-MIBI on vincristine cytotoxicity in
GLC4 and GLC4/ADR1,50x. Survival curves were performed in
GLC4 andGLC4/ADR150. cell lines for 1-h exposure to vincristine
(range 0 JM to 0.60 JM) plus and minus 99Tc-MIBI (ICIO or IC25).
Modulating effects were analysed by isobologram analysis
according to Steel and Peckman (1979). Three independent exper-
iments were performed, each in quadruplicate.
Statistics
Statistical significance was determined with the paired and
unpaired Student's t-test. Only P-values < 0.05 were considered to
be significant.
RESULTS
Cellular 99mTc-MIBI accumulation in A2780 and the
P-gp-overexpressing cell line A2780AD
Cellular accumulation after 1-h exposure to 64 fM 99mTc-MIBI was
much higher in A2780 (mean ± s.d. 35 x 10-4± 5 x 10-4 attomol
per 106 cells) than in A2780AD (0.43 x 10-4 0.03 x 10-4 attomol
per 106 cells) (P < 0.0005). Co-incubation with verapamil
increased the cellular 99mTc-MIBI accumulation to 15 x 10-4 3 x
10-4 attomol per 106 cells in A2780AD (P < 0.0025). Verapamil
did not affect the cellular 99mTc-MIBI accumulation in A2780.
Cellular 99mTc-MIBI accumulation and efflux in cell lines
with different MRP expression
Afterequal 99mTc-MIBI accumulation ofGLC4 and GLC4/ADR5SOx'
at 10 min after starting the efflux study, the cellular content
of 99-Tc-MIBI in GLC4/ADR150x was 46% compared with GLC4.
This illustrates that, at initially the same cellular 99-Tc-MIBI
accumulation, increased efflux exists in GLC4/ADRi50x compared
with GLC4.
Figure 1 shows that increasing doxorubicin resistance in
GLC4/ADR2x, GLC4/ADR10x and GLC4/ADRIsox coincided with a
decreasing 99mTc-MIBI accumulation after 1 h of991mTc-MIBI expo-
sure. Compared with GLC4 the cellular concentration of
99mTc-MIBI was lower, being 35%, 20% and 1.5% in GLC4/ADR2X,
GLC4/ADR,ox and GLC4/ADRl5ox respectively. Under the same
conditions, the cellular 99-Tc-MIBI accumulation was 0.13 ± 0.04
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Figure 3 Efflux of 99mTc-MIBI in GLC4 (0), GLC4/ADR2, (0), GLC4/ADRCOX
(A) and GLC4/ADR,c,, (V) cells. 99mTc-MIBI content was determined after
1-h SSmTc-MIBI incubation and at 10 min and 30 min (x-axis) with drug-free
medium and expressed as % of the radioactivity present after 1-h drug
exposure. Each point represents the mean ± s.d. of values obtained in three
independent experiments, each performed in duplicate. At t= 10 min, the
cellular 99mTc-MIBI concentration was lower in GLC4/ADR2, than in GLC4
(P< 0.025), there was no significant difference between GLC4/ADR,2 and
GLC4/ADR1O, and the cellular concentration in GLC4/ADR150X was lower than
in GLC4/ADR,0, (P< 0.05)
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Figure 5 Cell survival after 1-h incubation with 99Tc-MlBI in GLC4 (0) and
GLC4/ADRlCD (-). Each point represents the mean ± s.d. of two independent
expenments, each performed in quadruplicate. From a concentration of
200gmM 9Tc-MlBl, significantly more cytotoxicity was observed in GLC4 than
inGLC4/ADRC50, (P< 0.0005)
Effects of glutathione depletion on accumulation and
efflux of 99mTc-MIBI
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Figure 4 Efflux of 99mTc-MIBI in Si (0) and S1-MRP (0) cells. CDmTc-MIBI
content was determined after 1-h drug exposure and at 10 min and 30 min
with drug-free medium and expressed as a % ofthe radioactivity present
after 1-h drug exposure. Each point represents the mean ± s.d. of three
independent experiments, each performed in duplicate. At t = 10 min,
the cellular 99mTc-MIBI concentration was lower in S1-MRP than in S1
(P< 0.0025)
attomol per 106 cells in the MRP-transfected cell line S1-MRP and
0.43 ± 0.24 attomol per 106 cells in its parental cell line. Exposure
to 99mTc-MIBI plus vincristine increased the cellular 99mTc-MIBI
concentration significantly compared with 99mTc-MIBI exposure
alone (Figure 2). In the GLC4 sublines, the percentage of 99mTc-
MIBI efflux coincided with increase in doxorubicin resistance. Ten
minutes after starting the efflux study, the cellular 99mTc-MIBI
concentration was 76% in GLC4/ADR2X, 66% inGLC4/ADR1ox and
49% in GLC4/ADR150x compared with GLC4 (Figure 3). In Si-
MRP, the efflux was also increased compared with S1. The cellular
99-Tc-MIBI concentration after 10 min in drug-free medium was
39% in S1-MRP and 61% in SI (Figure 4).
Glutathione depletion by BSO followed by 1 h of 99mTc-MIBI
exposure increased the 99mTc-MIBI concentration in GLC4 to
182% compared with undepleted GLC4 cells. In glutathione-
depleted GLC4/ADR150 cells, the 99mTc-MIBI concentration
increased even more. This increase resulted in a cellular 99mTc-
MIBI concentration that differed, no longer significantly, from the
cellular 99-Tc-MIBI concentration in GLC4 (Figure 2).
Cell survival
Cell survival curves of GLC4 and GLC4/ADR5,OX cell lines after
exposure to 99Tc-MIBI are shown in Figure 5. Over the 99Tc-MIBI
concentration range tested, more cytotoxicity was observed in
GLC4 than in GLC4/ADR150x. The 99Tc-MIBI IC1O and IC25 were
50 gIM and 85 gIM, respectively, for GLC4 and 100 gM and
> 300 gIM, respectively, forGLC4/ADR15x. A modulation effect of
99Tc-MIBI(IC1Oand IC25) was observed on vincristine cytotoxicity
in GLC4/ADR150, butnotinGLC4. Isobologram analysis showed a
synergistic effect of 99Tc-MIBI on vincristine cytotoxicity in
GLC4/ADR151, (data not shown).
DISCUSSION
The present study demonstrates that in vitro 99mTc-MIBI is not only
a substrate forP-gpbutalso forMRP. The earlierresults ofPiwnica-
Worms et al (1993), which suggestthat99mTc-MIBI is a substrate for
P-gp, were confirmed. Co-incubation of99mTc-MLBI and verapamil
resulted in an increased cellular concentration of99mTc-MIBI in the
P-gp-overexpressing cell line A2780AD, while no effect was
observed in the doxorubicin-sensitive parental cell line.
Evidence that 99mTc-MIBI is also a substrate for MRP has been
obtained along various lines. In sublines of the human small-cell
lung carcinoma cell line GLC4, with varying degrees of doxoru-
bicin resistance and MRP content, it was shown that 99mTc-MIBI
accumulation was lower when MRP expression increased.
Versantvoort et al (1995a) observed, just as for 99mTc-MIBI, a
lower daunorubicin accumulation when MRP expression
increased in the GLC4 cell lines. Increased MRP expression in
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these cell lines was also shown to correlate with increased 99mTc-
MIBI efflux. In addition, incubation of GLC4 and GLC4/ADRl5Ox
with 99mTc-MIBI at 4°C to reach equal accumulation in absolute
terms confirmed increased 99mTc-MIBI efflux with increased MRP
expression. This indicates that 99mTc-MIBI efflux is not dependent
on the absolute cellular levels of 99mTc-MIBI, but efflux is depen-
dent on the rate of transport per minute. Co-incubation of 99mTc-
MIBI with vincristine resulted in higher 99mTc-MIBI levels in all
GLC4 cell lines. The fact that 99mTc-MIBI also increased by
vincristine co-incubation in the parental GLC4 cell line can be
explained by a low MRP expression in this cell line. The effects of
vincristine are most likely due to partial blocking of 99mTc-MIBI
efflux by vincristine.
Doxorubicin resistance in GLC4/ADR150x is multifactorial and
considered to be due to an increase in MRP, an increased detoxifi-
cation and decreased DNA topoisomerase II level (Zijlstra et al,
1987; Timmer-Bosscha et al, 1989; Simon et al, 1994). Therefore,
we also analysed the effect of 99mTc-MIBI on the non-small-cell
lung carcinoma cell line SI and its MRP-transfected subline S1-
MRP. Just as in the GLC4 cell lines, a lower accumulation and
increased efflux of 99mTc-MIBI was observed in SI-MRP
compared with the parental SI cell line.
Recently, it was shown that MRP functions as a glutathione S-
conjugate carrier (Jedlitschky et al, 1994; Leier et al, 1994; Muller
et al, 1994). This finding has stimulated studies with MDR drugs in
MRP-overexpressing cell lines after glutathione depletion with
BSO (Meijer et al, 1991; Versantvoort et al, 1995b; Zaman et al,
1995). Zaman et al (1995) observed a complete reversal of resis-
tance to doxorubicin, daunorubicin, vincristine and etoposide after
glutathione depletion in the MRP-transfected cell line S1-MRP.
Glutathione depletion also resulted in an increased 99-Tc-MIBI
accumulation from MRP-transfected cells. These BSO effects were
not observed in P-gp-overexpressing cell lines (Versantvoort et al,
1995b). In the present study, it was shown that glutathione deple-
tion inGLC4/ADR15ox almost fully restored the cellular99mTc-MIBI
level to the level obtained in GLC4. In addition, evaluation of the
enhancing effects of 99Tc-MIBI on vincristine cytotoxicity with
isobologram analysis according to Steel and Peckman (1979)
demonstrated that the blocking effects of99Tc-MIBI on vincristine
cytotoxicity in GLC4/ADRl5OX is synergistic. Cytotoxicity testing
revealed cross-resistance for 99Tc-MIBI between GLC4/ADR150x
and GLC4. The increased 99mTc-MIBI efflux, the effects of
glutathione depletion on cellular 99mTc-MIBI levels and the cross-
resistance for 9Tc-MIBI as well as increased cytotoxicity of
vincristine induced by 99Tc-MIBI in MRP-overexpressing cells
indicate that Tc-MIBI is a substrate for MRP. Tc-MIBI seems to
behave in a way similar to that of the chemotherapeutic drugs
involved in MRP-mediated MDR. Glutathione S-conjugates are
transported by MRP (Ishikawa, 1992) and, based on experiments
with inside-out vesicles, it is suggested that only substrates with a
hydrophobic part and at least two negative charges can be trans-
ported by MRP. There is still much debate in the literature on how
doxorubicin and vincristine are transported by MRP (Versantvoort
et al, 1995b; Zaman et al, 1995). Forthese chemotherapeutic drugs,
no glutathione S-conjugates have been identified. One possibility
might be that these conjugates are unstable and therefore not
detectable. Another hypothesis is that the chemotherapeutic drugs
are co-transported with glutathione by the MRP pump (Jedlitschky
etal, 1994; Leieretal, 1994; Mulleretal, 1994; Zaman etal, 1995).
99mTc-MIBI is a synthetic 7y-ray-emitting organotechnetium
complex. In vitro, it is a substrate for both P-gp and MRP.
Therefore, itmight be used in vivo for functional efflux imaging in
tumours. Efflux of 99-Tc-MIBI could then be extrapolated to the
efflux ofchemotherapeutic agents. This is ofpotential interest as it
is known that in drug-resistant cells both P-gp and MRP can be
overexpressed at the same time (Brock et al, 1995; Schuurhuis et
al, 1995). ForP-gp, several blockers are known, such as verapamil
and cyclosporin A, which enables the study ofthe functional efflux
inhibition of 99mTc-MIBI by these blockers from P-gp-positive
tumours. We are aware of the fact that verapamil and cyclosporin
A are not specific inhibitors for P-gp and affect to some extent
MRP (Twentyman et al, 1996). For MRP, it is suggested that
probenecid and sulfinpyrazone may be useful as specific reversal
agents for MRP-mediated drug resistance (Evers et al, 1996).
Therefore, clinical studies focusing on inhibition of 99mTc-MIBI
efflux with such compounds from MRP-positive tumours could be
a topic offurther investigation.
ABBREVIATIONS
ATP, adenosine triphosphate; BSO, D,L-buthionine S,R-sulphox-
imine; DMEM, Dulbecco's modified Eagle medium; DMF, dose-
modifying factor; FCS, fetal calf serum; ICIO, drug concentration
inhibiting survival by 10%; IC25, drug concentration inhibiting
survival by 25%; MDR, multidrug resistance; MRP, multidrug
resistance-associated protein; MTA, microculture tetrazolium
assay; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetra-
zolium bromide; P-gp, P-glycoprotein; PBS, phosphate-buffered
saline (0.14 M sodium chloride, 2.7 mm potassium chloride,
6.4 mm disodium hydrogen phosphate, 1.5 mm potassium dihy-
drogen phosphate, pH 7.4); RPMI 1640, Roswell Park Memorial
Institute 1640; Tc, Technetium; 99mTc-MIBI, 99mTc-sestamibi;
99Tc-MIBI, 99Tc-sestamibi.
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